{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Genetic studies of the αS gene in familial cases of PD and DLB have demonstrated that expression of abnormal αS or overexpression of normal αS is associated with these diseases.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that abnormal αS expression or overexpression of normal αS is associated with PD and DLB, establishing the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "E46K, A53T and A30P/A53T αS accelerated the formation of fαS, especially the elongation process compared with WT",
          "judgment": "Yes",
          "reasoning": "The paper uses in vitro fibrillization assays (M assays) which are directly relevant to the disease mechanism of αS aggregation in PD and DLB.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Not explicitly mentioned in the provided text",
          "judgment": "No",
          "reasoning": "The provided text does not mention whether basic controls (both 'Normal/Negative/Wild type' and 'Abnormal/Positive/Null' controls) were used or whether multiple replicates were used.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "M assays in vitro",
          "judgment": "Yes",
          "reasoning": "In vitro fibrillization assays (M assays) are broadly accepted standard techniques in the field of protein aggregation research.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T variant was shown to accelerate the formation of fibrillar αS, particularly the elongation process, compared to wild-type. While the paper doesn't provide details on controls or replicates, in vitro fibrillization assays are standard techniques in the field. This provides supporting evidence for pathogenicity."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Genetic studies of the αS gene in familial cases of PD and DLB have demonstrated that expression of abnormal αS or overexpression of normal αS is associated with these diseases.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that abnormal αS expression or overexpression of normal αS is associated with PD and DLB, establishing the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "A30P αS decelerated the formation of fαS, especially the elongation process",
          "judgment": "Yes",
          "reasoning": "The paper uses in vitro fibrillization assays (M assays) which are directly relevant to the disease mechanism of αS aggregation in PD and DLB.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Not explicitly mentioned in the provided text",
          "judgment": "No",
          "reasoning": "The provided text does not mention whether basic controls (both 'Normal/Negative/Wild type' and 'Abnormal/Positive/Null' controls) were used or whether multiple replicates were used.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "M assays in vitro",
          "judgment": "Yes",
          "reasoning": "In vitro fibrillization assays (M assays) are broadly accepted standard techniques in the field of protein aggregation research.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant was shown to decelerate the formation of fibrillar αS, particularly the elongation process, compared to wild-type. While the paper doesn't provide details on controls or replicates, in vitro fibrillization assays are standard techniques in the field. This provides supporting evidence for pathogenicity."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Genetic studies of the αS gene in familial cases of PD and DLB have demonstrated that expression of abnormal αS or overexpression of normal αS is associated with these diseases.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that abnormal αS expression or overexpression of normal αS is associated with PD and DLB, establishing the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "E46K, A53T and A30P/A53T αS accelerated the formation of fαS, especially the elongation process compared with WT",
          "judgment": "Yes",
          "reasoning": "The paper uses in vitro fibrillization assays (M assays) which are directly relevant to the disease mechanism of αS aggregation in PD and DLB.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Not explicitly mentioned in the provided text",
          "judgment": "No",
          "reasoning": "The provided text does not mention whether basic controls (both 'Normal/Negative/Wild type' and 'Abnormal/Positive/Null' controls) were used or whether multiple replicates were used.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "M assays in vitro",
          "judgment": "Yes",
          "reasoning": "In vitro fibrillization assays (M assays) are broadly accepted standard techniques in the field of protein aggregation research.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The E46K variant was shown to accelerate the formation of fibrillar αS, particularly the elongation process, compared to wild-type. While the paper doesn't provide details on controls or replicates, in vitro fibrillization assays are standard techniques in the field. This provides supporting evidence for pathogenicity."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A30P/A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Genetic studies of the αS gene in familial cases of PD and DLB have demonstrated that expression of abnormal αS or overexpression of normal αS is associated with these diseases.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that abnormal αS expression or overexpression of normal αS is associated with PD and DLB, establishing the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "E46K, A53T and A30P/A53T αS accelerated the formation of fαS, especially the elongation process compared with WT",
          "judgment": "Yes",
          "reasoning": "The paper uses in vitro fibrillization assays (M assays) which are directly relevant to the disease mechanism of αS aggregation in PD and DLB.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Not explicitly mentioned in the provided text",
          "judgment": "No",
          "reasoning": "The provided text does not mention whether basic controls (both 'Normal/Negative/Wild type' and 'Abnormal/Positive/Null' controls) were used or whether multiple replicates were used.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "M assays in vitro",
          "judgment": "Yes",
          "reasoning": "In vitro fibrillization assays (M assays) are broadly accepted standard techniques in the field of protein aggregation research.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The double variant A30P/A53T was shown to accelerate the formation of fibrillar αS, particularly the elongation process, compared to wild-type. While the paper doesn't provide details on controls or replicates, in vitro fibrillization assays are standard techniques in the field. This provides supporting evidence for pathogenicity."
    }
  ]
}